

1 **Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-**
2 **Frequency Hearing Loss in Cystic Fibrosis**

3
4 Chelsea M. Blankenship^{1,2}, Lisa L. Hunter¹, M. Patrick Feeney^{3,4}, Madison Cox¹, Lindsey
5 Bittinger¹, Angie Garinis^{3,4}, Li Lin⁵, Gary McPhail⁶, John P. Clancy⁶

6
7 ¹ Communication Sciences Research Center, Cincinnati Children's Hospital Medical Center,
8 Cincinnati, Ohio. USA.

9 ² Departments of Otolaryngology and Communication Sciences and Disorders, University of
10 Cincinnati, Cincinnati, Ohio. USA.

11 ³ Oregon Hearing Research Center, Oregon Health & Science University, Portland, OR. USA.

12 ⁴ National Center for Rehabilitative Auditory Research, VA Portland Health Care System,
13 Portland, OR. USA.

14 ⁵ Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
15 USA.

16 ⁶ Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati,
17 Ohio. USA.

18
19
20
21
22
23
24
25
26
27

28 **Conflicts of Interest and Source of Funding:**

29 This research was supported by the National Institute Health, National Institute on Deafness and
30 Other Communication Disorders Grant R01DC010202 (multi-principal investigators: Doug
31 Keefe, Lisa L. Hunter and Patrick Feeney), National Institute of Health, Clinical and Translational
32 Science Award Program Grant 5UL1TR001425-04 (Center for Clinical and Translational Science
33 Training at the University of Cincinnati) and the Cincinnati Children's Hospital Medical Center
34 Research Foundation Place Outcomes Research Award (multi-principle investigators: Lisa L.
35 Hunter and John P. Clancy).

36

37 Address correspondence to Chelsea Blankenship, Communication Sciences Research Center,
38 Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio 45229,
39 USA. E-mail: chelsea.blankenship@cchmc.org

40 **Abstract**

41 **Purpose:** The purpose of this study is to better understand the prevalence of ototoxicity-related
42 hearing loss and its functional impact on communication in a pediatric and young adult cohort with
43 cystic fibrosis (CF) and individuals without CF (controls).

44 **Method:** Observational, cross-sectional investigation of hearing function in children, teens, and
45 young adults with CF (n = 57, mean = 15.0 yr.) who received intravenous aminoglycoside
46 antibiotics and age- and gender-matched controls (n = 61, mean = 14.6 yr.). Participants completed
47 standard and extended high frequency audiometry, middle ear measures, speech perception tests,
48 and a hearing and balance questionnaire.

49 **Results:** Individuals with CF were 3 to 4 times more likely to report issues with hearing, balance,
50 and tinnitus and performed significantly poorer on speech perception tasks compared to controls.
51 A higher prevalence of hearing loss was observed in individuals with CF (57%) compared to
52 controls (37%). CF and control groups had similar proportions of slight and mild hearing losses,
53 however individuals with CF were 7.6 times more likely to have moderate and greater degrees of
54 hearing loss. Older participants displayed higher average EHF thresholds, with no effect of age on
55 average SF thresholds. Although middle ear dysfunction has not previously been reported to be
56 more prevalent in CF, this study showed that 16% had conductive or mixed hearing loss and higher
57 rates of previous otitis media and pressure equalization (PE) tube surgeries compared to controls.

58 **Conclusions:** Individuals with CF have a higher prevalence of conductive, mixed and
59 sensorineural hearing loss, poorer speech-in-noise performance and higher rates of multiple
60 symptoms associated with otologic disorders (tinnitus, hearing difficulty, dizziness, imbalance and
61 otitis media) compared to controls. Accordingly, children with CF should be asked about these
62 symptoms, receive baseline hearing assessment(s) prior to treatment with potentially ototoxic

63 medications, and at regular intervals thereafter in order to provide otologic and audiologic
64 treatment for hearing and ear-related problems to improve communication functioning.

65 **Keywords**

66 Cystic fibrosis, Ototoxicity, Speech-in-Noise

67

68 **Abbreviations**

69 Air-Conduction (AC); Aminoglycoside (AG); Bamford-Kowal-Bench Speech-in-Noise (BKB-
70 SIN); Bone-conduction (BC); Cincinnati Children's Hospital Medical Center (CCHMC);
71 Conductive Hearing Loss (CHL); Cystic Fibrosis (CF); Extended High Frequency (EHF);
72 Intravenous-Aminoglycoside (IV-AG); Mixed Hearing Loss (MHL); Normal Hearing (NH);
73 Pressure Equalization (PE); Signal-to-Noise Ratio (SNR); Sensitive (Frequency) Range for
74 Ototoxicity (SRO); Sensorineural Hearing Loss (SNHL); Speech Reception Threshold (SRT);
75 Standard Frequency (SF);

76

77

78

79

80

81

82

83

84

85

86 **Introduction**

87 Cystic fibrosis (CF) is the most common congenital life-threatening genetic disease in
88 Caucasians occurring in 1/2500 births and affecting over 70,000 individuals worldwide ([Cystic](#)
89 [Fibrosis Foundation, 2017](#); [Kreicher, Bauschard, Clemmens, Riva, & Meyer, 2018](#)). Individuals
90 with CF experience recurrent pulmonary infections that are commonly treated with intravenous
91 aminoglycoside (IV-AG) and glycopeptide antibiotics ([Barclay et al., 1996](#); [Becker & Cooper,](#)
92 [2013](#); [Jiang, Karasawa, & Steyger, 2017](#); [O'Sullivan et al., 2017](#)). Due in part to the aggressive IV-
93 AG treatment, the predicted median age of survival for patients with CF has increased from 28
94 years in 1989 to 43 years in 2016 with the number of survivors over 40 years of age doubling
95 every 5 years ([Cystic Fibrosis Foundation, 2017](#)). Individuals with CF often require repeated doses
96 of IV-AG treatment throughout life, and thus are at a higher risk of developing permanent
97 sensorineural hearing loss (SNHL; cochleotoxicity) and balance disorders (vestibulotoxicity;
98 Ariano et al., 2008; Garinis et al., 2017; Handelsman et al., 2017; Tan et al., 2003). In some cases,
99 the effects of ototoxicity can be severe and life altering. The stark reality of going deaf due to
100 aminoglycoside (AG) antibiotics was poignantly written in the words of Brad Dell, a 25-year-old
101 man with cystic fibrosis, “I’ll never forget the day of nothing. Hearing absolutely nothing. The
102 remainder of my hearing had leaked out of my ears as more amikacin doses leaked into my veins”
103 ([Dell, 2018](#)). As hearing loss progresses, speech perception is subsequently affected, highlighting
104 the importance of speech perception assessment in ototoxicity monitoring programs.

105 Aminoglycoside (e.g., amikacin, tobramycin and gentamicin) and glycopeptide (e.g.,
106 vancomycin) antibiotics remain the primary treatment agent of choice for CF pulmonary
107 exacerbations and are in widespread use in CF centers ([Barclay et al., 1996](#); [Becker & Cooper,](#)
108 [2013](#); [Jiang et al., 2017](#); [O'Sullivan et al., 2017](#)). They are cost-effective and highly efficient
109 against gram-negative organisms, such as *Pseudomonas aeruginosa*, which are the underlying

110 cause of pulmonary lung infections in CF ([Conway, Miller, Ramsden, & Littlewood, 1985](#); [Szaff,](#)
111 [Hoiby, & Flensburg, 1983](#)). The median age at which *Pseudomonas aeruginosa* infections first
112 occurs is 5.2 years. Using the Leeds classification criteria, 46.6% of all individuals with CF have
113 *Pseudomonas aeruginosa*, while 28.6% are chronic and necessitate repeated courses of IV-AG
114 treatment ([Cystic Fibrosis Foundation, 2017](#)). While treatment with AGs alone or in conjunction
115 with glycopeptides is common practice to treat life-threatening bacterial infections, these
116 antibiotics have a well-documented ototoxic effect, resulting in irreversible damage to hearing and
117 balance structures within the inner ear ([Handelsman, Nasr, Pitts, & King, 2017](#); [Liu et al., 2013](#);
118 [Pauna, Monsanto, Kurata, Paparella, & Cureoglu, 2017](#); [Sone, Schachern, & Paparella, 1998](#)).
119 Ototoxicity can result as a direct effect of AGs, with gentamicin considered to be primarily
120 vestibulotoxic, and amikacin and tobramycin mainly cochleotoxic. However, in theory they can
121 all induce damage to both parts of in the inner ear ([Jiang et al., 2017](#); [Selimoglu, 2007](#)).
122 Glycopeptide antibiotics (e.g., vancomycin) can indirectly cause hearing loss due to their
123 synergistic effect with AGs. For example, vancomycin is highly nephrotoxic, resulting in
124 decreased kidney function/renal clearance of AGs potentially leading to an increased susceptibility
125 to developing hearing loss ([Filippone, Kraft, & Farber, 2017](#)).

126 The cochleotoxic effect of aminoglycosides, with or without glycopeptides, is
127 characterized by SNHL that originates in the basal turn of the cochlea. Within the high frequency
128 region, outer hair cell loss occurs first followed by inner hair cell loss after which damage
129 progresses to the apical region affecting lower frequencies ([Fausti et al., 1984](#); [Guthrie, 2008](#);
130 [Huizing & de Groot, 1987](#)). Thus, extended high frequency (EHF; > 8 kHz) audiometry is integral
131 to ototoxicity monitoring due to the progression of hearing loss from high to low frequencies
132 ([Fausti, Frey, Henry, Olson, & Schaffer, 1993](#); [Fausti et al., 1992](#); [Fausti et al., 1994](#)). Furthermore,

133 [Fausti et al. \(1999\)](#) identified a sensitive (frequency) range for ototoxicity (SRO) which focuses
134 on the highest frequencies that are audible to an individual patient. The SRO method involves
135 defining the highest audible frequency and then measuring pure-tone thresholds in one-sixth
136 octaves up to the predetermined frequency limit. This shortened ototoxicity monitoring test
137 decreases overall test time to approximately 10 minutes and maintains a 90% detection rate of
138 significant changes in hearing ([Fausti et al., 2003](#); [Fausti et al., 1999](#)).

139 The prevalence of hearing loss in children with CF repeatedly treated with IV-AGs ranges
140 from 0 to 44% ([Al-Malky, Dawson, Sirimanna, Bagkeris, & Suri, 2015](#); [Thomsen, Friis, Jensen,](#)
141 [Bak-Pedersen, & Larsen, 1979](#)) and extends up to 59% in adults ([Garinis et al., 2017](#); [Scheenstra,](#)
142 [Heijerman, Zuur, Touw, & Rijntjes, 2010](#); [Zettner & Gleser, 2018](#)). Substantial variability in
143 prevalence rates occurs across studies due to differences in the population studied, type of AG and
144 potential co-administration of glycopeptides, mode of drug administration, total body clearance of
145 the drug, total number of AG doses, individual susceptibility, audiologic test protocol and hearing
146 loss criteria. In general studies that only included the standard frequencies (SF; 0.25 to 8 kHz)
147 found lower rates of hearing loss ([Cheng et al., 2009](#); [Forman-Franco, Abramson, Gorvoy, & Stein,](#)
148 [1979](#); [Ozcelik et al., 1996](#); [Stavroulaki et al., 2002](#)) compared to studies that included EHF
149 audiometry ([Al-Malky et al., 2015](#); [Al-Malky, Suri, Dawson, Sirimanna, & Kemp, 2011](#); [Garinis](#)
150 [et al., 2017](#); [Martins, Camargos, Becker, Becker, & Guimaraes, 2010](#); [Pedersen, Jensen,](#)
151 [Osterhammel, & Osterhammel, 1987](#)). In pediatric patients, [Al-Malky et al. \(2015\)](#) and [Cheng et](#)
152 [al. \(2009\)](#) reported a 3 to 24% prevalence of SNHL with less than 10 doses of IV-AGs that
153 increased to 40-44% with recurrent AG exposure (> 10 doses). In mostly adults with CF,
154 individuals with higher cumulative doses of IV-AGs were 4.5 times more likely to have hearing
155 loss compared to individuals with lower cumulative doses ([Garinis et al., 2017](#)). In a recent

156 retrospective examination of the prevalence and type of hearing loss in the pediatric CF population,
157 31.8% had hearing loss in at least one ear in the SF region ([Kreicher et al., 2018](#)). Further analysis
158 of the type of hearing loss (considering each ear separately) showed that 74.1% had normal
159 hearing, 5.3% had conductive loss, 2.3% sensorineural loss, 5.1% mixed hearing loss, and 13.2%
160 undefined ([Kreicher et al., 2018](#)).

161 Even though the use of EHF audiometry was first reported in the 1980s ([Ahonen &](#)
162 [McDermott, 1984](#); [Fausti et al., 1984](#); [McRorie, Bosso, & Randolph, 1989](#)), nearly 40 years later
163 it is still not routinely used in audiology clinics to monitor changes in hearing due to ototoxicity.
164 Potential explanations include lack of clear ototoxicity monitoring guidelines and protocols, time
165 constraints, audiology equipment and staffing limitations, absence of EHF audiometry
166 reimbursement codes, as well as outcome data that indicate preserving EHF is important and has
167 a positive impact on overall quality of life. A survey of Cystic Fibrosis Foundation Accredited
168 Care Centers and Affiliated Programs reported that while 43% of clinics performed audiological
169 evaluations, it is unclear if EHF were included and some centers only measured thresholds if the
170 patient was symptomatic ([Van Meter, Corriveau, Ahern, & Lahiri, 2009](#)). More recently, [Prescott](#)
171 [\(2011\)](#) reported that 39% of pediatric CF programs do not monitor for ototoxicity at all, 32% of
172 clinics monitor hearing in the SF range, and 46% include EHF audiometry. In addition, less than
173 half of published pediatric studies of AG associated ototoxicity include EHF audiometry. This
174 likely because most pediatric CF studies are retrospective. Since EHF audiometry is not routinely
175 used in clinical practice, the onset and true prevalence of ototoxic hearing loss is likely
176 underestimated.

177 In contrast to the common misconception that EHF contribute very little to speech
178 understanding, substantial information occurs at frequencies above 8 kHz that can be used for

179 localization, speaker identification, and phoneme identification. [Alexander, Kopun, and](#)
180 [Stelmachowicz \(2014\)](#) reported fricatives /ch, f, j, s, sh, th, v, and z/ contain differential spectral
181 information from 3 to 10 kHz that can be used for phoneme identification. Furthermore, EHF
182 spectral information aides in vowel and consonant identification when access to SF energy is
183 restricted or degraded ([Lippmann, 1996](#); [Vitela, Monson, & Lotto, 2015](#)) or when extended
184 bandwidth hearing aids improve audibility of EHF's ([Seeto & Searchfield, 2018](#)). EHF improves
185 sound localization by providing cues to resolve front/back confusions ([Best, Carlile, Jin, & van](#)
186 [Schaik, 2005](#); [Brungart & Simpson, 2009](#); [Heffner & Heffner, 2008](#)) and can help listeners identify
187 the speaker and segregate their voice from background talkers ([Monson, Rock, Schulz, Hoffman,](#)
188 [& Buss, 2019](#)). In adults, [Yeend, Beach, and Sharma \(2019\)](#) reported poorer EHF thresholds are
189 significantly correlated with poorer speech understanding in noise on the Listening in Spatialized
190 Noise Task high-cue condition ([Cameron & Dillon, 2007](#)), and increased self-report of listening
191 difficulties (Speech, Spatial and Qualities of Hearing; [Gatehouse & Noble, 2004](#)). Additionally,
192 [Motlagh Zadeh et al. \(2019\)](#) reported that adults with self-reported difficulty following
193 conversations in noise were more likely to have EHF hearing loss (>20 dB HL).

194 Early detection of hearing loss is extremely important in pediatric patients due to its
195 documented impact on speech and language development, literacy development ([Yoshinaga-Itano,](#)
196 [1999, 2003](#)), and scholastic achievement ([Moeller, Tomblin, Yoshinaga-Itano, Connor, & Jerger,](#)
197 [2007](#)). Children and teens with CF that receive greater or more frequent doses of ototoxic
198 antibiotics will likely experience EHF hearing loss that accumulates over time into adulthood. ([Al-](#)
199 [Malky et al., 2015](#); [Al-Malky et al., 2011](#); [Garinis et al., 2017](#)). As AG ototoxicity damage
200 progresses from base to apex, frequencies in the human speech range will ultimately be involved,
201 causing a permanent communication disability. Although EHF hearing loss is assumed to be

202 associated with progressive declines in speech perception ([Besser, Festen, Goverts, Kramer, &](#)
203 [Pichora-Fuller, 2015](#); [Hunter et al., 2020b](#); [Levy, Freed, Nilsson, Moore, & Puria, 2015](#); [Motlagh](#)
204 [Zadeh et al., 2019](#)), there is little if any published data on speech-in-noise performance in
205 individuals with CF and AG exposure. Furthermore, the functional impact of speech understanding
206 in noise is highly relevant for environments that children and adults listen in, such as the classroom,
207 workplace, and social settings. Other notable limitations of previous studies include absence of
208 EHF audiometry or bone-conduction (BC) thresholds, which limits their ability to accurately
209 identify the presence and classify type of hearing loss. Most studies did not include an age-matched
210 control group to make a direct and accurate comparison to the general population. Lastly, as
211 previously mentioned, none included a functional measure of hearing loss on daily communication
212 or evaluation of patient and parent perception of perceived hearing difficulties. These patient-
213 reported outcomes are critical for improving patient-centered clinical care approaches and for
214 improving communication between the patient and their clinical care team.

215 The goal of this study was to better understand the prevalence of ototoxicity-related hearing
216 loss and its functional impact on communication in a pediatric cohort with CF. In order to achieve
217 this goal, we examined SF and EHF audiometry (air- and bone-conduction), tympanometry, and
218 middle ear muscle reflexes (MEMR) to fully describe hearing function in children with CF
219 children and age- and gender-matched controls. A standardized pediatric measure of speech-in-
220 noise as well as a self-report questionnaire for patients and parents on perceived hearing and
221 balance difficulties and the functional impact of hearing loss on communication was also
222 completed.

223 **Materials and Methods**

224 *Participants*

225 The study was part of a larger longitudinal project to evaluate the prevalence of hearing
226 loss in children and adults with CF in relation to the concentration of AG-drug exposure and
227 toxicologic response (pharmacodynamics), including ototoxic outcomes. Children and young
228 adults diagnosed with CF (n = 57, mean age = 15.0 yr., range = 6.0 to 21.0) who received
229 tobramycin or amikacin IV antibiotics, alone or in combination with vancomycin were recruited
230 from the CF inpatient unit at Cincinnati Children's Hospital Medical Center (CCHMC). Age- and
231 gender-matched controls (n = 61, mean age = 14.6 yr., range = 7.5 to 21.1) were recruited from
232 the same hospital through internal staff emails and outpatient study flyers. Additional eligibility
233 criteria for both the CF and control group included ages between 6-21 years of age and the ability
234 to complete a conventional behavioral hearing test. Controls were not excluded based on hearing
235 status in order to provide a more accurate representation of the hearing levels of the general
236 population. They had no history of AG treatment, and no CF diagnoses. The study was approved
237 by the CCHMC Institutional Review Board. Informed parental consent and child assent (for ages
238 9-17 years) or patient consent (ages 18 and older) was obtained prior to enrollment. All participants
239 were reimbursed for their participation.

240 *Test Protocol*

241 All participants completed comprehensive diagnostic assessments including otoscopy,
242 226-Hz tympanometry, MEMRs, SF and EHF audiometric assessment, and speech understanding
243 in quiet and noise. A hearing and balance questionnaire was administered to determine if the
244 participant or the parent reported any hearing difficulties, tinnitus, balance disturbance, history of
245 otitis media, PE tubes, or previous hearing exams. Additional details regarding onset, frequency

246 and type of symptoms, and family history of hearing loss were also queried (see questionnaire in
247 Appendix 1). This was a non-validated questionnaire, comparable to a case history or intake
248 questionnaire that would be filled out during a clinical audiology appointment. All test procedures
249 were completed in a double-walled sound booth (Industrial Acoustics Company, North Aurora,
250 Illinois). Otoscopy was completed first to ensure the ear canal was patent, and if necessary,
251 cerumen was removed. The test protocol took approximately one hour to complete. Individuals
252 with CF completed testing while they were inpatient at CCHMC, while controls were tested during
253 an outpatient research appointment.

254 Audiometric Assessment: Air-conduction (AC) thresholds were obtained with an Equinox
255 Audiometer (Interacoustics Inc., Middlefart, Denmark) and Sennheiser HDA-300 circumaural
256 headphones (Old Lyme, CT) in the SF range at octave test frequencies from 0.25 to 8 and in the
257 EHF range (10, 12.5, 14 and 16 kHz). Calibration was completed according to ISO 389.8 ([2004](#))
258 for SF and ISO 389-1 ([2017](#)) for EHF. Bone-conduction (BC) thresholds were measured using a
259 Radio-ear B-71 bone oscillator (Radioear Corp, New Eagle, PA) at 0.25, 0.5, 1, 2, and 4 kHz if
260 AC thresholds were ≥ 20 dB HL with appropriate narrowband masking in the contralateral ear. A
261 modified Hughson-Westlake procedure with a 5-dB step size was used to measure threshold. For
262 both the SF and EHF range, audiometric thresholds were used to categorize each ear based on the
263 presence, degree, and type of hearing loss as well as the ear affected (left, right, bilateral). The
264 degree of hearing loss was classified according to [Goodman \(1965\)](#) and [Northern and Downs](#)
265 [\(1984\)](#) criteria for the pure-tone average for 0.5, 1, and 2 kHz: normal (0 to 15 dB HL), slight (16-
266 25 dB HL), mild (26-40 dB HL), moderate (41-55 dB HL), moderately-severe (56-70 dB HL),
267 severe (71-90 dB HL), and profound (91 + dB HL). The type of hearing loss was classified as
268 follows:

- 269 1. Normal Hearing (NH): AC and BC thresholds within the normal range (≤ 15 dB HL).
- 270 2. Conductive Hearing Loss (CHL): BC thresholds less than or equal to 15 dB HL, air-
271 conduction thresholds greater than 15 dB, and an air-bone gap of 10 dB at two frequencies
272 or 20 dB at one frequency. For some participants abnormal tympanometry values were
273 used to diagnose conductive loss (see criteria below in 226-Hz Tympanometry
274 description).
- 275 3. Sensorineural Hearing Loss (SNHL): AC and BC thresholds greater than 15 dB HL
276 without an air-bone gap (defined under CHL) at any test frequency.
- 277 4. Mixed Hearing Loss (MHL): Presence of a sensorineural and conductive hearing loss at
278 the same audiometric test frequency or within the same ear.

279 Middle Ear Measures: Middle ear function was measured using a traditional 226-Hz
280 tympanometry using the Titan (Interacoustics Inc., Middelfart, Denmark). Individuals were not
281 excluded due to middle ear dysfunction. If BC thresholds were not measured (due to time restraints
282 or patient fatigue), tympanometry values were used to determine if there was a conductive
283 component to the hearing loss with the following normative ranges for tympanometric peak
284 pressure (-100 to +30 daPa), admittance (0.3 to 1.5 mmho) and tympanometric width (30 to 105
285 daPa; Roup et al., 1998). At least two out of three values needed to be identified as abnormal (i.e.,
286 outside normative range) for the individual to be classified as having a conductive component to
287 the hearing loss.

288 Middle Ear Muscle Reflexes (MEMR). MEMRs were assessed using the Titan (Interacoustics Inc.,
289 Middelfart, Denmark) clinical system alone, or in combination with a research wideband
290 absorbance technique with custom designed recording system. MEMR thresholds were measured
291 using a broadband noise stimulus in ipsilateral (same ear) and contralateral (opposite ear)

292 conditions. In both systems, ear canal air pressure was adjusted to the peak tympanometric pressure
293 obtained during wideband tympanometry (results not reported here). For the Interacoustics Titan
294 clinical system, the broadband stimuli (0.5 to 8 kHz) were presented from 60 to 100 dB SPL in 5
295 dB steps. An ascending technique was used where the lowest intensity that evoked a reflex using
296 a “very sensitive” criteria of 0.02 ml was marked as threshold. With the research wideband
297 absorbance technique, MEMRs were measured using a pulsed-activator stimulus set that included
298 four broadband noise activator (0.25 to 8 kHz) pulses that alternated with five wideband (0.25 to
299 8 kHz) clicks. Stimulus levels were calibrated in a 2-cm (HA-1) coupler and were presented in 5-
300 dB steps from 60 to 120 dB peSPL. MEMRs measured with the research wideband absorbance
301 technique used response averaging, artifact rejection and signal processing techniques to measure
302 threshold, onset latency and amplitude growth. Additional details regarding the measurement and
303 analysis procedures may be found in [Keefe, Feeney, Hunter, and Fitzpatrick \(2017\)](#). The control
304 group had relatively equal percentages of MEMRs measured using the Titan (52%) compared to
305 the wideband research technique (48%). In comparison, the CF group had a higher percentage of
306 MEMRs measured with the wideband research technique (68%) compared to the Titan (32%).
307 Since the wideband technique results in lower MEMR thresholds, a correction factor was applied
308 in order to combine MEMR measured using the two different recording systems. The correction
309 factor was based on MEMR thresholds measured from a group of children from a separate study
310 using an identical MEMR test protocol ([Hunter et al., 2020a](#)). The children all had typical
311 development and normal hearing in the SF region. That normative sample included 48 children
312 with typical development (93 ears) with normal hearing that ranged in age from 6.5 to 14.5 (mean
313 = 10.0 yr.). The correction factor applied to the research-based thresholds was 15.5 dB and 12.5
314 dB SPL for the ipsilateral and contralateral MEMR reflexes, respectively.

315 Speech Perception Testing. A speech reception threshold (SRT) was measured for each ear, using
316 recorded spondees from the Central Institute for the Deaf W-1 adult or child word list ([Auditec,](#)
317 [2015](#); [Hirsch et al., 1952](#)). Speech understanding in noise was evaluated using the Bamford-
318 Kowal-Bench Speech-in-Noise (BKB-SIN) test measured at 50 dB HL in the monaural condition
319 with 1 list pair administered to each ear ([Etymotic Research, 2005](#)). This is an adaptive measure
320 with signal-to-noise ratio (SNR) values ranging from +21 to -6 dB and is representative of
321 environments that occur in the classroom and everyday settings. The participants were instructed
322 to repeat each sentence that they heard and to guess if they were unsure. The number of key words
323 repeated correctly for each sentence was tallied and used to calculate the SNR in dB necessary for
324 the individual to understand 50% of the sentence (SNR-50). The SNR-Loss was calculated as the
325 individual SNR-50 minus age-matched normative SNR-50 values from the BKB-SIN manual. The
326 SNR-Loss is used to determine how much greater a SNR is needed for the individual to have
327 equivalent performance to their age-matched peers. Additionally, the SNR-Loss can be categorized
328 as follows to indicate the degree of difficulty understanding speech-in-noise: 1.) Normal is 0 to 3
329 dB, 2.) Mild is greater than 3 to 7 dB, 3.) Moderate is greater than 7 to 15 dB, 4.) Severe is greater
330 than 15 dB ([Etymotic Research, 2005](#)).

331 *Statistical Analysis*

332 Descriptive statistics were used to summarize demographics and outcome measurements
333 to identify any errors and outliers. Interval variables were summarized by central tendency and
334 dispersion, and categorical variables were described by frequencies and percentages. Two-sample
335 t-test, Chi-Square test or Fisher Exact tests were performed as appropriate to compare the
336 demographics between the CF and control groups. Boxplots were created to study the distribution
337 of the outcome variables. Mixed models were conducted to study the differences between the CF

338 and control groups, with Test Ear included as a repeated measure and demographic factors
339 included as covariates (Age at Test, Sex, and Race). Where appropriate, Test Frequency was
340 included as a repeated measure and Hearing Status was included as a fixed effect factor. Interaction
341 terms were also studied, and in some cases were removed from the final adjusted model for a
342 parsimonious model due to their insignificance ($p > 0.05$). Sidak adjustment was applied for
343 pairwise comparisons among the significant factors. Pearson correlations were used to assess the
344 relationship between audiometric thresholds, SNR-Loss, and Age at Test. All data were collected
345 and managed using REDCap, which is a secure web-based software platform ([Harris et al., 2019](#);
346 [Harris et al., 2009](#)) and then exported and formatted for analysis using SAS statistical software
347 version 9.3 (SAS Institute, Cary, N.C.). Two-sided significance level was set at 0.05 for all
348 analyses.

349 **Results**

350 *Cohort Characteristics*

351 A total of 74 individuals with CF were approached for the study, however 10 individuals
352 were not interested in participating (14%) and 7 individuals were consented but were unable to
353 complete testing prior to discharge (9%) resulting in 57 individuals that were enrolled and
354 completed test procedures (77%). A control group of children without CF (control; $n = 61$) were
355 enrolled and completed testing. Therefore, the study included 118 participants, 57 individuals with
356 CF (49%), and 61 controls (51%). For individuals with CF, the mean age at test was 15.0 years
357 (SD = 3.6, range = 6.0 to 21.0), 42% were males and 98% were Caucasian. In the control group,
358 the mean age at test was 14.6 years (SD = 2.9, range = 7.5 to 21.1), 46% were males, and 85%
359 were Caucasian. There were no significant group differences in Age at Test and Sex however the

360 control group had a higher number of non-Caucasians than the CF group. See Table 1 for additional
361 group characteristics.

362

363 --- Insert Table 1. Here ---

364

365 *Hearing and Balance Questionnaire*

366 Parent and participant hearing and balance questionnaire responses were combined to
367 determine an overall response for each question for each participant. Questions regarding hearing
368 concerns, tinnitus, and balance issues were binary (Yes/No), while history of otitis media, PE tubes
369 and previous hearing test were categorical (Yes/No/Not sure). Additional details regarding onset,
370 frequency and type of symptoms were also queried (see questionnaire in Appendix 1). Table 1
371 displays the number of individuals within the CF and control group and corresponding percentages
372 that indicated “Yes” to symptoms included in the questionnaire. Chi-square tests were performed
373 to examine differences in hearing and balance concerns between the CF and control group.
374 Individuals with CF reported significantly more hearing concerns (CF = 32%, Control = 8%),
375 tinnitus (CF = 53%, Control = 16%), and balance problems including dizziness, unsteadiness or
376 imbalance (CF = 32%, Control = 9%) compared to controls. Individuals with CF were also more
377 likely to have a history of middle ear infections than controls (CF = 42%, Control = 26%).
378 Although non-significant, the CF group reported a slightly higher history of PE tubes (CF = 16%,
379 Control = 11%) with controls reporting a higher percentage of having a previous hearing test (CF
380 = 82%, Control = 89%).

381

382 *Audiometric Thresholds*

383 Descriptive statistics for prevalence, degree and type of hearing loss are displayed in Table
384 1. Individuals with CF had a significantly higher prevalence of hearing loss in either the SF or
385 EHF ranges (57%) compared to controls (37%). Within the CF group, 38% had hearing loss in the
386 SF range; the majority (88%) had slight to mild hearing loss while a smaller percentage (12%) had
387 moderate to moderate-severe hearing loss. In the EHF range, 47% of individuals with CF had
388 hearing loss, with almost equal percentages of slight to mild hearing loss (52%) and moderate to
389 severe hearing loss (48%). In the control group, only 37% had hearing loss; 17% of control ears
390 had hearing loss in the SF range and 30% had hearing loss in the EHF range. Of the control ears
391 with hearing loss in the SFs, the degree of loss only ranged from slight to mild with no greater
392 degrees of hearing loss present. In the EHF range, most controls had hearing loss in the slight to
393 mild range (89%), with few ears in the moderate to moderately severe range (11%). When
394 examining the degree of hearing loss across all audiometric frequencies, the CF and control group
395 have similar numbers of slight and mild hearing losses, however individuals with CF had much
396 greater percentages of moderate and greater degrees of hearing loss (CF = 23%, Control = 3%).
397 With regard to the type of hearing loss, 5% of the CF group had a CHL, 41% had SNHL, and 11%
398 had MHL. Controls mainly had SNHL (29%), with smaller percentages of CHL (2%) and MHL
399 (5%).

400 The CF and control group mean audiometric thresholds and 95% confidence intervals are
401 displayed as a function of test frequency in Figure 1, top panel. The CF group had significantly
402 poorer audiometric thresholds compared to controls across all test frequencies ($p < 0.001$; See
403 Table 2). Audiometric thresholds varied significantly across frequency, with poorer thresholds at
404 0.25 and 0.5 kHz and in the EHF range (14 to 16 kHz; $p < 0.001$). The interaction between Group
405 and Test Frequency was significant ($p < 0.001$), since the mean difference between groups was not

406 constant across all test frequencies. With regard to Race, Caucasians had significantly better
407 audiometric thresholds compared to non-Caucasians ($p = 0.004$). Minimal mean threshold
408 differences (± 1 dB HL) were observed from 0.25 to 8 kHz. However, at 10 and 12.5 kHz,
409 Caucasians had mean thresholds that were 7-8 dB HL better than non-Caucasians and at 14 to 16
410 kHz mean thresholds were 2 to 3 dB better. Main effects of Test Ear, Sex, and Age at Test were
411 not significant ($p > 0.05$).

412 In Figure 1, bottom panel, the CF group was separated into a normal hearing (CF-NH) and
413 hearing loss group (CF-HL; >15 dB HL at a minimum of one audiometric test frequency), with
414 the control group mean thresholds plotted for comparison. When the CF group was subdivided
415 based on hearing status, the control and CF-NH group had similar thresholds from 0.25 to 16 kHz.
416 For the CF-HL group, although thresholds are poorer across all test frequencies, the most
417 pronounced difference was from 8 to 16 kHz where maximum thresholds ranged from 55 to 75 dB
418 HL compared to maximum thresholds of 20 to 40 dB HL in the control group in the same frequency
419 range.

420 Pearson correlation analysis was conducted to examine the relationship between participant
421 Age at Test and average thresholds in the SF and EHF range. With all participants combined, a
422 significant positive relationship was found between Age at Test and average EHF thresholds ($r =$
423 $.183$, $p = 0.005$) but not for the average SF thresholds ($r = .075$, $p = 0.249$). Results indicate that
424 older participants displayed higher average EHF thresholds with no difference in SF thresholds.

425

426 --- Insert Figure 1. Here ---

427 --- Insert Table 2. Here ---

428

429

430 *Middle Ear Function*

431 Middle ear function was analyzed using repeated measures analysis to determine if there
432 were differences between CF and control groups (see Table 2). A fixed effect of Hearing Status
433 was included, where participants were categorized based on the type of hearing loss (NH, SNHL,
434 and CHL/MHL categories). For tympanometric peak pressure, a significant effect of Group was
435 not observed ($p < 0.05$; CF = -41.2 daPa, Control = -46.3 daPa), however Hearing Status ($p =$
436 0.001) and Sex ($p = 0.002$) were both significant in the model. Pairwise comparisons showed
437 similar peak pressure for individuals with NH (mean = -19.0 daPa) and SNHL (mean = -22.4
438 daPa). Significantly decreased middle ear pressure was found for participants with a CHL/MHL
439 (mean = -89.8 daPa). With regard to Sex, females (mean = -16.1 daPa) had significantly increased
440 peak pressure compared to males (mean = -43.2 daPa).

441 The CF group had significantly higher admittance (mean = 1.1 mmho) using 226-Hz
442 tympanometry compared to controls (mean = 0.7 mmho; $p = 0.002$). Although Hearing Status was
443 not significant, there was a significant Group by Hearing category interaction ($p = 0.041$). Controls
444 had similar admittance across Hearing Status groups (NH = 0.7 mmho, CHL/MHL = 0.6 mmho,
445 SNHL = 0.8 mmho). Within the CF group, individuals with hearing loss had higher admittance
446 (CHL/MHL = 1.5 mmho, SNHL = 1.1 mmho) than those with normal hearing (NH = 0.8 mmho).
447 An effect of Age at Test, Ear, or Race did not reach significance in any model for the middle ear
448 function variables ($p > 0.05$). Additionally, for tympanometric width, there were no significant
449 effects for any of the factors included in the model ($p > 0.05$).

450 *MEMR*

451 A significant effect of Group and Hearing Status (hearing loss at any one frequency >15 dB
452 HL) was found for both ipsilateral and contralateral MEMR thresholds. For the ipsilateral

453 condition, the CF group had slightly lower MEMR thresholds (mean = 84.5 dB SPL) compared to
454 controls (mean = 88.3 dB SPL; $p = 0.042$). Similarly, for the contralateral condition, individuals
455 with CF had slightly lower MEMR thresholds (mean = 88.3 dB SPL) compared to controls (mean
456 = 92.8 dB SPL; $p = 0.004$). Participants with hearing loss had higher MEMR thresholds than
457 individuals with normal hearing for both the ipsilateral (NH = 83.7 dB SPL, HL = 89.1 dB SPL; p
458 < 0.001) and contralateral conditions (NH = 87.5 dB SPL, HL = 92.8 dB SPL; $p = 0.001$). No
459 significant effects were found for Test Ear, Age at Test, Sex, or Race for either ipsilateral or
460 contralateral MEMR thresholds ($p > 0.05$). See Table 2 for repeated measures analysis results and
461 Figure 2 for MEMR boxplots.

462

463

--- Insert Figure 2. Here ---

464 *Speech Perception*

465 Individuals with CF showed significantly higher SRT (mean = 13.8 dB HL) compared to the
466 control (mean = 9.5 dB HL; $p < 0.001$). In the CF group, SRTs ranged from 0 to 35 dB HL, with
467 81% of ears having a normal SRT and 19% with an SRT greater than 15 dB HL. In the control
468 group, the SRT ranged from 0 to 20 dB HL with 94% of ears having a normal SRT value, and only
469 6% with an elevated SRT. Test Ear, Age at Test, Sex, and Race were not significant ($p > 0.05$).

470 For SNR-Loss (age-adjusted scores), individuals with CF had significantly poorer (higher)
471 SNR values (mean = 2.5 dB HL) compared to controls (mean = 1.1 dB; $p < 0.001$; Figure 3, left).
472 Within the control group, 96% of ears had normal SNR-Loss (range = -2.8 to 3.0 dB) while only
473 4% had a mild SNR-Loss (range = 3.5 to 4.4 dB). For the CF group, the SNR-Loss ranged from -
474 1.1 to 10.0 dB HL; 64% of ears had normal SNR-Loss and 36% of ears had mild or moderate SNR-
475 Loss. In addition to a significant Group effect, individuals with HL (CF and control groups

476 combined) had slightly higher SNR-Loss (mean = 2.2 dB) compared to those with NH (mean =
477 1.5 dB; $p = 0.045$; Figure 3, middle). Lastly, females had significantly higher SNR-Loss values
478 (mean = 2.1 dB) compared to males (mean = 1.4 dB; $p = 0.017$). When the CF group was
479 subdivided based on the presence of hearing loss, 25% of individuals with CF and normal hearing
480 had abnormal SNR-Loss (range = 3.5 to 6 dB). In contrast, 45% of individuals with CF and hearing
481 loss had abnormal SNR-Loss (range = 3.2 to 10 dB; Figure 3, right).

482 To further evaluate the relationship between hearing status and speech understanding in noise,
483 SNR-Loss was plotted against mean audiometric thresholds in the SF (0.25 to 8 kHz) and EHF
484 (10-16 kHz) range for the CF-NH, CF-HL, and controls (see Figure 4). Correlation analysis
485 completed with all participants combined showed a significant positive relationship for both the
486 average SF ($r = .301, p < 0.001$) and EHF ($r = .116, p = 0.022$) thresholds compared to SNR-Loss.
487 The SF range had a stronger relationship with SNR-Loss, explaining a greater amount of variance
488 (9%) compared to the EHF range (3%). Lastly, upon comparison of perceived hearing concerns
489 and the speech-in-noise performance, only 53% of the CF group with SNR-Loss reported hearing
490 concerns on the questionnaire while 47% with an abnormal SNR-Loss reported no hearing
491 concerns. Furthermore, only 37% of individuals with CF and hearing loss (any frequency >15 dB
492 HL) reported hearing concerns on the questionnaire while 63% with hearing loss reported no
493 hearing concerns.

494

495 --- Insert Figure 3. Here ---

496 --- Insert Figure 4. Here ---

497

498 **Discussion**

499 The main purpose of this study was to determine the prevalence of ototoxicity-related
500 hearing loss, tinnitus, and balance and the functional impact on communication in a pediatric
501 cohort with CF compared to age- and gender-matched controls. The CF group had a significantly
502 higher prevalence of hearing loss in either the SF or EHF region (57%) compared to the control
503 group (37%). The majority of controls with hearing loss, had slight-to-mild degrees of loss. In
504 contrast, individuals with CF had high percentages of mild-to-moderate hearing loss, with some
505 individuals displaying moderate-to-severe and severe degrees of hearing loss. The CF group also
506 had a higher prevalence of CHL or MHL (16% combined) compared to controls (7%). Individuals
507 with CF were also more likely to have a history of middle ear infections and PE tubes than controls.
508 Lastly the CF group reported significantly more hearing concerns, tinnitus, balance problems than
509 controls, had higher speech recognition thresholds in quiet, and performed poorer on a clinical
510 speech understanding in noise task.

511 *Prevalence of Hearing Loss*

512 This study showed a very high rate of hearing loss in both the standard (38%) and extended
513 high frequency region (47%) for children, teens and young adults with CF who have received IV-
514 AG antibiotics to treat lung exacerbations. Estimates of hearing loss vary in part due to the criterion
515 for normal-hearing; our study included slight hearing loss (>15 dB HL) in either the SF or EHF
516 range, so the estimates are higher than studies that have used more conservative criteria (e.g.,
517 Stavroulaki et al., 2002; Solmaz et al., 2016). Using hearing loss criteria similar to the current
518 study, [Al-Malky et al. \(2011\)](#) reported clinically normal hearing (0 to 15 dB HL) from 0.25 to 12.5
519 kHz in children with CF (n = 45) and little to no previous exposure to IV-AGs (≤ 5 courses).
520 However, in a high IV-AG exposure group (mean = 17.6 courses, range = 6 to 37), 35% of

521 individuals with CF had evidence of ototoxicity in the EHF region, defined as any threshold \geq 20
522 dB HL. Similarly, [Al-Malky et al. \(2015\)](#) reported ototoxicity in 24% of children with CF and
523 previous exposure to IV-AGs, but in the high exposure group (range = 10 to 40 courses), 44%
524 displayed ototoxicity with thresholds ranging from 25 to 85 dB HL.

525 In contrast, several studies have reported much lower rates of hearing loss, possibly due to
526 less stringent hearing loss criteria or the exclusion of EHF audiometry. For example, [Stavroulaki
527 et al. \(2002\)](#) reported normal thresholds (\leq 20 dB HL) from 0.25 to 8 kHz in a pediatric CF cohort
528 with a history of gentamicin exposure (n = 12; range = 5.2 to 14.1 yr.) at baseline and following
529 gentamicin treatment (4mg/kg/day; mean = 14 days; range = 11 to 29). [Solmaz et al. \(2016\)](#)
530 reported 12% of individuals with CF (mean = 8.3 yr.; range = 5 to 13) with more than 3 courses
531 of IV amikacin had hearing loss when using a pure-tone average (0.5, 1, 2, and 4 kHz) greater than
532 25 dB HL. However, when the hearing loss threshold was decreased to $>$ 15 dB HL, 80% of ears
533 in the CF group had hearing loss. In contrast, all individuals in the control group had normal
534 hearing from 0.25 to 8 kHz by the more conservative criterion. In a large retrospective study of
535 hearing impairment, [Kreicher et al. \(2018\)](#) reported 31.8% of individuals with CF (mean = 8.3 yr.)
536 had hearing loss in at least one ear ($>$ 15 dB HL at any frequency from 0.25 to 8 kHz). Most ears
537 with hearing loss showed a slight to mild loss (15%) with a smaller number of moderate to
538 profound losses (3%). [Martins et al. \(2010\)](#) reported only 4% of a CF group (range = 0.4 to 18 yr.)
539 displayed ototoxicity when the hearing loss criteria was based on a pure-tone average (0.5, 1, 2
540 kHz) $>$ 25 dB HL. However, the rate of hearing loss increased to 11% when a criterion of two or
541 more frequencies $>$ 25 dB HL from 0.25 to 12 kHz was implemented. Lastly, [Geyer, Menna
542 Barreto, Weigert, and Teixeira \(2015\)](#) reported that both the CF and control group had normal
543 hearing in the SF region (pure-tone average of 0.25 to 8 kHz). However, in the CF group, 30.8%

544 had at least one threshold greater than 25 dB HL in the EHF region (9-16 kHz), compared to 2.8%
545 in the control group. When comparing thresholds across individual test frequencies, the CF group
546 had significantly higher audiometric thresholds at 0.25, 1, 8, 9, 12.5 and 16 kHz compared to the
547 control group ([Geyer et al., 2015](#)).

548 The prevalence of hearing loss in a pediatric and young adults with CF observed in the
549 current study (57%) is comparable to studies conducted with mainly adults with CF and a higher
550 hearing loss criterion (e.g., [Garinis et al., 2017](#); [Zettner & Folsom, 2003](#)). [Zettner and Gleser](#)
551 [\(2018\)](#) examined the progression of hearing loss in a group of 165 adults with CF and previous
552 AG-IV exposure (mainly tobramycin) over a 10-year period. At the first audiometric examination,
553 [Zettner and Gleser \(2018\)](#) reported 59% of CF group had hearing loss (≥ 25 dB HL at any
554 frequency from 2 to 16 kHz) which progressed to 75% by their last hearing evaluation. [Garinis et](#)
555 [al. \(2017\)](#) reported 56% of individuals with CF displayed hearing loss (>25 dB HL at any
556 frequency from 0.25 to 16 kHz). Even after accounting for age and gender effects, [Garinis et al.](#)
557 [\(2017\)](#) reported a significant negative effect of cumulative IV-AG doses on audiometric
558 thresholds. Individuals with the highest IV-AG exposure (152 to 647 doses) were 4.79 times more
559 likely to have SNHL compared to individuals with relatively low exposure (2 to 15 doses). Several
560 other studies have also reported increased rates of hearing loss with repeated IV-AG exposure ([Al-](#)
561 [Malky et al., 2015](#); [Al-Malky et al., 2011](#); [Cheng et al., 2009](#); [Mulherin et al., 1991](#); [Pedersen et](#)
562 [al., 1987](#)). However, some individuals with CF and a relatively low cumulative IV-AG doses still
563 present with significant hearing loss across the standard and extended high frequency region ([Al-](#)
564 [Malky et al., 2015](#); [Garinis et al., 2017](#)) indicating that a simple linear relationship between hearing
565 and IV-AG exposure does not exist. Rather ototoxicity is the result of a complex interaction
566 between multiple different factors, which will influence the onset and progression of hearing loss

567 ([Mulheran, Degg, Burr, Morgan, & Stableforth, 2001](#); [Smyth, 2010](#)). Additional risk factors that
568 have been associated with increased ototoxicity include frequent hospitalizations and poorer lung
569 function ([Al-Malky et al., 2015](#); [Tarshish et al., 2016](#)), concomitant use of vancomycin ([Al-Malky](#)
570 [et al., 2015](#); [O'Donnell et al., 2010](#)), diabetes ([Kreicher et al., 2018](#)), mitochondrial mutations, ([Al-](#)
571 [Malky et al., 2015](#)), and Hispanic or Asian ethnicity ([Knight, Kraemer, & Neuwelt, 2005](#);
572 [O'Donnell et al., 2010](#)).

573 *Importance of EHF's in Ototoxicity Monitoring*

574 It is well established that aminoglycoside induced hearing loss originates in the EHF region
575 and with increased IV-AG exposure, eventually progresses to the SF region ([Fausti et al., 2003](#);
576 [Fausti et al., 1999](#)). Therefore, the inclusion of EHF audiometry when monitoring for ototoxicity
577 is essential. Several studies have evaluated the presence of hearing loss based on frequency region.
578 For example, Al-Malky et al. (2015) showed that the use of EHF (9-16 kHz) audiometry identified
579 15 children with hearing loss, while SF audiometry only detected 13 children. When using a SF
580 pure-tone average (0.5, 1, 2 kHz), [Martins et al. \(2010\)](#) reported only 4% of CF cases had hearing
581 loss (> 25 dB HL), however when EHF's (9-12 kHz) were included, 11% had hearing loss. [Geyer](#)
582 [et al. \(2015\)](#) reported that while all individuals with CF had normal hearing in the SFs, 30.8% of
583 the CF group had EHF hearing loss (9-16 kHz). Furthermore, [Garinis et al. \(2017\)](#) identified 45
584 individuals with CF with hearing loss (>25 dB HL at any frequency from 0.25 to 16 kHz), of which
585 28 participants only displayed hearing loss at frequencies > 9 kHz. Hearing loss in the
586 aforementioned studies is presumed to be sensorineural since the studies excluded individuals with
587 history of chronic middle ear infections, abnormal middle ear status, middle ear effusion, tympanic
588 membrane perforation, or conductive hearing loss verified with BC thresholds. In the current
589 study, 38% of the CF group had hearing loss in the SF and 47% had hearing loss in the EHF region.

590 When examining audiometric thresholds across frequency region, 15 individuals with CF (n = 22
591 ears, 7 bilateral, 8 unilateral) had normal hearing in the SFs but displayed either slight to mild (n
592 = 16 ears) or moderate to moderately-severe (n = 6 ears) hearing loss in the EHF. Therefore, the
593 use of only SF audiometry would result in the misdiagnosis of 15 individuals with CF with normal
594 hearing, when they display evidence of significant ototoxicity in the EHF. Furthermore, older
595 participants (CF and controls grouped together) displayed higher average EHF thresholds, with no
596 effect of age on average SF thresholds. Since individuals in the study are still very young, this may
597 suggest more treatment exposure for individuals with CF when the groups are separated out.

598 *Conductive Hearing Loss and History of Otitis Media*

599 The mucosal epithelium of the middle ear and eustachian tube is contiguous with the upper
600 respiratory track. Thus, it was previously assumed that individuals with CF may have a higher than
601 usual incidence of middle ear disease. However, temporal bone studies of individuals with and
602 without CF have shown similar pneumatization and mucosal histology of the middle ear ([Berkhout
603 et al., 2014](#); [Seifert et al., 2010](#); [Todd & Martin, 1988](#); [Yildirim et al., 2000](#)). In addition, several
604 studies have suggested that individuals with CF are at no higher risk than age-matched controls,
605 with some studies showing lower rates of inflammatory ear disease compared to controls ([Bak-
606 Pedersen & Larsen, 1979](#); [Cepero et al., 1987](#); [Cipolli et al., 1993](#); [Forcucci & Stark, 1972](#);
607 [Jorissen, De Boeck, & Feenstra, 1998](#); [Martins et al., 2011](#)). However, most previous studies did
608 not include bone conduction audiometry, and if tympanometry was included, individuals with
609 middle ear issues were excluded (otitis media, tympanic membrane perforation). Therefore, most
610 studies were not designed to detect conductive hearing loss or middle ear disorders, which may
611 help to explain why this issue has gone unrecognized.

612 Previously in the CF literature, the prevalence of otitis media have ranged from 3 to 45%.
613 A retrospective analysis of 450 individuals with CF revealed only 3% had a history of otologic
614 disease with only 1% receiving PE tubes ([Cepero et al., 1987](#)). In a CF group (n = 80), [Forman-](#)
615 [Franco et al. \(1979\)](#) reported 24% had a history of acute otitis media and only one individual had
616 received PE tubes. [Bak-Pedersen and Larsen \(1979\)](#) reported slightly higher rates of a history of
617 acute otitis media (35%) in a cohort of 111 individuals with CF. In a retrospective pediatric and
618 adult cohort study, [Cheng et al. \(2009\)](#) reported 20% had a history of middle ear effusion and or
619 eustachian tube dysfunction and abnormal tympanometry (Type B and C). Most recently, [Kreicher](#)
620 [et al. \(2018\)](#) conducted a retrospective study of 217 children with CF and found 45% had acute
621 otitis media and 29% were diagnosed with chronic otitis media. The number of otitis media
622 infections across patients ranged from 1 to 66, with an average of 6.6 per patient. PE tubes were
623 placed in 8% of the CF group and 23% were diagnosed with Eustachian tube dysfunction. Of the
624 94 ears with tympanometry results, 19% had abnormal tympanograms (type B and C).

625 With regard to the prevalence of CHL in individuals with CF, previous studies have
626 reported relatively low percentages ranging from 0 to 10% ([Al-Malky et al., 2015](#); [Al-Malky et](#)
627 [al., 2011](#); [Geyer et al., 2015](#); [Martins et al., 2010](#)). In a group of children and adults with CF (n =
628 80) with previous tobramycin and gentamicin exposure, [Forman-Franco et al. \(1979\)](#) reported no
629 individuals displayed CHL. [Pedersen et al. \(1987\)](#) reported a slightly higher rate, with 7% of
630 individuals with CF diagnosed with a CHL. Using BC thresholds measured from 0.25 to 4 kHz,
631 [Kreicher et al. \(2018\)](#) reported that 10% had a conductive component to their hearing loss, with
632 equal percentages of conductive (5.3%) and mixed (5.1%) loss. Lastly in a cohort of 70 children
633 with CF, [Kulczycki, Butler, McCord-Dickman, and Herer \(1970\)](#) reported a much higher rate with
634 27% of study participants showing a mild conductive loss.

635 In the present study, 118 participants (CF = 57, Control = 61) were investigated with the
636 use of the traditional approach of audiometric and otologic verification to detect and identify ear
637 disease. In addition, 226-Hz tympanometry and MEMRs were performed. The physiologic data
638 were used to analyze the pressure in the middle ear space, integrity and mobility of the tympanic
639 membrane and ossicles, and stapedius muscle function. We found that 42% of participants with
640 CF reported a history of chronic otitis media, 16% have had PE tube surgery, and 16% had a
641 conductive component to their hearing loss, compared to 26%, 11% and 7% in the control group,
642 respectively. Thus, compared to an age and gender matched sample, our CF group had significantly
643 more reports of past otitis media with effusion and PE tube placement. The occurrence of CHL in
644 our sample was mostly mild and was not accompanied by current otitis media with effusion or flat
645 tympanometry. Rather, in most cases, tympanometry showed significantly more negative peak
646 pressure in the ears with CHL, indicating Eustachian tube dysfunction. Most cases of CHL also
647 showed abnormally high admittance for tympanometry, although this was not statistically
648 significant in terms of hearing loss type overall. Histories of PE tubes are frequently associated
649 with high admittance due to tympanic membrane defects related to either spontaneous perforation
650 or myringotomy of the tympanic membrane ([Hunter & Blankenship, 2017](#)).

651 The finding of lower (better) MEMR thresholds in individuals with CF and AG exposure
652 for both ipsilateral and contralateral stimuli has not been reported previously and does not have a
653 clear explanation (However, see Westman et al., 2020 in this volume). While MEMR thresholds in
654 the present study were overall slightly lower in the CF group, MEMR thresholds were poorer for
655 individuals with hearing loss. This result was expected and is consistent with changes in MEMRs
656 due to outer hair cell loss in kanamycin exposure ([Borg & Engström, 1982](#)). Validation in another

657 sample, and with non-AG exposed participants is needed to explore the finding of better MEMR
658 in patients with normal hearing.

659 *Functional Impact*

660 While most previous studies have focused on audiometric assessment it is important to
661 evaluate the functional impact of the hearing loss on the individual and their communication
662 abilities. In the current study, 32% of individuals with CF reported hearing difficulties and 53%
663 reported tinnitus compared to 8% and 16% in the control group, respectively. In comparison, [Al-](#)
664 [Malky et al. \(2015\)](#) reported that most children with ototoxicity did not report any issues with
665 hearing or tinnitus. Of the 15 individuals with CF that displayed hearing loss, only four reported
666 issues with both hearing and tinnitus, two had hearing difficulties, and one child reported issues
667 with tinnitus. The remaining 8 children with ototoxicity did not report any issues with hearing or
668 tinnitus. Similarly, [Mulheran et al. \(2001\)](#) reported 17% of the CF group had significant
669 ototoxicity, many with hearing loss that had progressed into the SF region. Yet most of these
670 individuals were asymptomatic; none of the patients had self-report of hearing difficulties and only
671 four individuals experienced periodic tinnitus during treatment. Clinical measures of speech
672 understanding in quiet and noise are important tools to evaluate the impact of hearing impairment
673 on communication abilities. The CF group had significantly poorer speech recognition thresholds
674 and speech-in-noise scores compared to age-matched controls. For speech understanding in quiet,
675 6% of controls had an abnormal SRT (>15 dB HL) compared to 19% of the CF group. On the
676 BKB-SIN, 64% of the CF group had an abnormal SNR-Loss that ranged from mild to moderate,
677 yet only 4% of the controls had an abnormal SNR-Loss, all within the mild range. While 45% of
678 individuals with CF with hearing loss also had an abnormal SNR-Loss, 25% of individuals with
679 CF and normal hearing displayed an abnormal SNR-Loss. Although several studies have reported

680 that speech perception was conducted as part of the audiometric test battery, test results were not
681 provided/reported ([Forman-Franco et al., 1979](#); [Martins et al., 2010](#); [Pedersen et al., 1987](#)).
682 [Forcucci and Stark \(1972\)](#) conducted audiometric, otologic and speech-language examinations
683 in a group of 31 children with CF and 22% had deficient speech-language development. Due to
684 the cumulative ototoxic nature of IV-AG, individuals with CF are at a higher risk for developing
685 hearing loss that can impact speech and language development, literacy development, scholastic
686 achievement, and overall quality of life ([Moeller et al., 2007](#); [Yoshinaga-Itano, 1999, 2003](#)),
687 ([Moeller et al., 2007](#)). Therefore, ototoxicity monitoring/management programs should include
688 functional impact measures that can be administered quickly, ideally at the patient bedside or at
689 home. Even if the AG treatment schedule cannot be altered to minimize ototoxicity, self-report
690 measures and clinical speech perception assessments are necessary to evaluate the impact of
691 hearing loss and to identify individuals for audiologic treatment. Additionally, there is a substantial
692 lack of patient-reported outcomes in ototoxicity monitoring programs which are critical for patient-
693 centered clinical care.

694 Very few studies have reported the effects of AG treatment on vestibular function in
695 individuals with CF ([Handelsman et al., 2017](#); [Scheenstra, Rijntjes, Tavy, Kingma, & Heijerman,](#)
696 [2009](#)). Furthermore, studies report wide variability in presence of vestibular impairments and very
697 little has been reported about vestibular asymmetries. [Scheenstra et al. \(2009\)](#) reported 35% of
698 adults with CF had either a peripheral or central impairment as diagnosed using
699 Electronystagmography with caloric irrigation, while only 16% self-reported vestibular issues on
700 a questionnaire. In a group of children and adults with CF, [Handelsman et al. \(2017\)](#) reported that
701 while most underreported symptoms, 79% had vestibular system dysfunction based on diagnostic
702 test battery (dynamic visual acuity, videonystagmography, sinusoidal and rotational step testing).

703 In the current study 32% of the CF group reported balance issues compared to 16% in controls.
704 The presence of vestibular impairments is high among individuals with CF, yet most go
705 undiagnosed due to lack of testing and underreport of patient symptoms. Vestibular assessments
706 that can be performed quickly with minimal physical or psychological discomfort, such as the
707 video head impulse test and vestibular evoked myogenic potential test, should be included in
708 ototoxicity monitoring programs.

709 *Limitations and Future Directions*

710 The primary limitation of this study is that individuals with CF had pre-existing exposure
711 to AGs, and thus nearly half had pre-existing hearing loss as well. Efforts are underway to continue
712 longitudinal assessment of this sample, and to expand the assessment to children not yet exposed
713 to ascertain onset and progression of hearing loss in future studies. In process for this study is
714 analysis of past doses of AGs, and pharmacodynamic measures (peak, trough blood levels and
715 deeper tissue estimation of drug exposure over time) to determine relationships to hearing loss and
716 changes over time with repeated hearing tests. While the sample size is relatively modest, it is one
717 of the largest studies published specifically in children with prospective assessment. Diabetes and
718 genetic variants that are related to AG ototoxicity as well as known mutations (Ex: m1555A>G
719 mutation) that increase risk for developing hearing loss will be included in future studies.

720 **Conclusion**

721 Individuals with CF are at extremely high risk for developing hearing loss and balance
722 disorders due to routine exposure of IV-AGs to treat pulmonary exacerbations. As the predicted
723 median age of survival for individuals with CF continues to increase, many will become exposed
724 to very high cumulative doses of IV-AG, thereby increasing their risk for developing hearing loss.
725 Our results showed high rates of SNHL and CHL in the CF group, higher than most pediatric CF

726 studies due to the inclusion of EHF audiometry and a more stringent hearing loss criteria (threshold
727 at any frequency >15 dB HL). Furthermore, older participants display higher average EHF
728 thresholds, with no effect of age on average SF thresholds. Studies that based the presence of
729 hearing loss on the individual thresholds within the SF region, a SF pure-tone average, or higher
730 significant threshold criteria (dB HL) are likely underestimating the incidence of hearing loss in
731 this population. Furthermore, these individuals with CF displayed high rates of middle ear
732 dysfunction and conductive hearing loss, a problem that has not been identified in studies that did
733 not include bone conduction or excluded individuals with abnormal middle ear status.

734 Previous studies have not reported speech perception in either quiet or noise. Our study
735 shows that SNHL connected with AG use degrades the listener's ability to perceive speech-in-
736 noise which may diminish quality of life and has clear educational implications. The impacts of
737 broadened tuning resulting from EHF hearing loss on speech-in-noise are just beginning to be
738 appreciated ([Besser et al., 2015](#); [Hunter et al., 2020b](#)), but have received scant attention in patients
739 with ototoxicity. The importance of speech communication for patients with chronic illness also
740 has implications for ongoing care. Medical staff must wear masks due to contact isolation
741 requirements, and they report that communication is challenging with their patients with hearing
742 loss. Armed with evidence of ototoxicity, physicians report that they are willing to consider
743 treatment modifications to minimize permanent hearing loss and the impact on communication
744 ([Garinis et al., 2018](#)). The BKB-SIN test used in this study to evaluate speech-in-noise
745 performance are derived from child language samples and the sentences are at approximately a
746 first-grade reading level ([Nilsson, Soli, & Sullivan, 1994](#)). The test is adaptive, avoiding ceiling
747 and floor effects, has ecological validity and is reportedly not confounded by language abilities
748 and working memory ([Magimairaj, Nagaraj, & Benafield, 2018](#)). However, other studies have

749 found that sentence in noise performance is associated with language and working memory in
750 children ([McCreery, Spratford, Kirby, & Brennan, 2017](#)). The BKB-SIN test yields a SNR-Loss
751 score that is age-normalized, allowing results to be compared across different populations.
752 Inclusion of an age- and language-appropriate speech-in-noise measure is recommended both to
753 evaluate functional effects of ototoxicity, and to assess the need for, and benefit of amplification.

754 Lastly, these the CF group reported significantly more issues with hearing (32%), tinnitus
755 (53%), and balance (32%), compared to controls (8%, 16%, 9%), respectively. However, self-
756 report of hearing difficulties was not predictive of hearing loss or speech-in-noise performance,
757 thus self-report cannot replace formalized testing to monitor for evidence of ototoxicity.

758

759 **Acknowledgments**

760 This research was supported by the National Institutes of Health, National Institute on Deafness
761 and Other Communication Disorders Grant R01DC010202 (multi-principal investigators: Doug
762 Keefe, Lisa L. Hunter and Patrick Feeney), National Institutes of Health, Clinical and Translational
763 Science Award Program Grant 5UL1TR001425-04 (Center for Clinical and Translational Science
764 Training at the University of Cincinnati) and the Cincinnati Children's Hospital Medical Center
765 Research Foundation Place Outcomes Research Award (multi-principle investigators: Lisa L.
766 Hunter and John P. Clancy). The content of this manuscript is solely the responsibility of the
767 authors and does not reflect the official views of the National Institute of Health or Cincinnati
768 Children's Hospital Medical Center. Portions of this study were presented at the World Congress
769 of Audiology 2018, North American Cystic Fibrosis Conference 2019, and the Association for
770 Research in Otolaryngology 2020. We also thank our participants, their families, and Summer
771 Undergraduate Research Foundation (SURF) scholars.

772

773 **Figure Legends**

774 **Figure 1.** Standard and extended high frequency audiometric thresholds measured in decibel
775 Hearing Level (dB HL) and calibrated according to ISO 389-8 and 389-1 (ISO, 2004, 2017). Top
776 panel: Mean and 95% CI for the CF and control group. Bottom panel: Mean and 95% CI for
777 controls with the CF group further classified into a normal hearing (CF-NH) and hearing loss (CF-
778 HL) group.

779 **Figure 2.** Ipsilateral and contralateral MEMR thresholds boxplots for the CF and control group
780 (top panel) and hearing status (bottom panel). Hearing loss was defined as thresholds >15 dB HL
781 at any test frequency (0.25-16 kHz) and included normal hearing (NH) and hearing loss (HL)
782 categories. Boxplots show median (line), interquartile range (boxes), 95% CI (stems) and outliers
783 (dots).

784 **Figure 3.** SNR-Loss displayed based on participant group (left), hearing status (middle) and lastly
785 with the CF group further classified into a normal hearing (CF-NH) and hearing loss (CF-HL)
786 group (right). Error bars indicate 95% confidence intervals.

787 **Figure 4.** SNR-Loss plotted as a function of average hearing thresholds for the control group with
788 the CF group further classified into a normal hearing (CF-NH) and hearing loss (CF-HL) group.
789 Standard frequency average thresholds (SF; 0.25 to 8 kHz) are displayed on the left and extended
790 high frequency average thresholds (EHF; 10-16 kHz) are displayed on the right. Regression lines
791 and the coefficient of determination are displayed in each figure.

792

793

794 **References**

- 795 Ahonen, J. E., & McDermott, J. C. (1984). Extended high-frequency hearing loss in children with
796 cleft palate. *Audiology*, *23*(5), 467-476. doi:10.3109/00206098409070086
- 797 Al-Malky, G., Dawson, S. J., Sirimanna, T., Bagkeris, E., & Suri, R. (2015). High-frequency
798 audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic
799 fibrosis. *J Cyst Fibros*, *14*(2), 248-254. doi:10.1016/j.jcf.2014.07.009
- 800 Al-Malky, G., Suri, R., Dawson, S. J., Sirimanna, T., & Kemp, D. (2011). Aminoglycoside
801 antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using
802 extended high-frequency audiometry and distortion product otoacoustic emissions. *Int J*
803 *Audiol*, *50*(2), 112-122. doi:10.3109/14992027.2010.524253
- 804 Alexander, J. M., Kopun, J. G., & Stelmachowicz, P. G. (2014). Effects of frequency compression
805 and frequency transposition on fricative and affricate perception in listeners with normal
806 hearing and mild to moderate hearing loss. *Ear Hear*, *35*(5), 519-532.
807 doi:10.1097/aud.0000000000000040
- 808 Ariano, R. E., Zelenitsky, S. A., & Kassum, D. A. (2008). Aminoglycoside-induced vestibular
809 injury: maintaining a sense of balance. *Ann Pharmacother*, *42*(9), 1282-1289.
810 doi:10.1345/aph.1L001
- 811 Auditec, I. (2015). *Spondees and Child Spondees* [Audio CD]. St. Louis, MO: Auditec
812 Incorporated.
- 813 Bak-Pedersen, K., & Larsen, P. K. (1979). Inflammatory middle ear diseases in patients with cystic
814 fibrosis. *Acta Otolaryngol Suppl*, *360*, 138-140. doi:10.3109/00016487809123499
- 815 Barclay, M. L., Begg, E. J., Chambers, S. T., Thornley, P. E., Pattemore, P. K., & Grimwood, K.
816 (1996). Adaptive resistance to tobramycin in *Pseudomonas aeruginosa* lung infection in
817 cystic fibrosis. *J Antimicrob Chemother*, *37*(6), 1155-1164. doi:10.1093/jac/37.6.1155
- 818 Becker, B., & Cooper, M. A. (2013). Aminoglycoside antibiotics in the 21st century. *ACS Chem*
819 *Biol*, *8*(1), 105-115. doi:10.1021/cb3005116
- 820 Berkhout, M. C., van Rooden, C. J., Aalbers, R. C., el Bouazzaoui, L. H., Fokkens, W. J., Rijntjes,
821 E., & Heijerman, H. G. (2014). Temporal bone pneumatization in cystic fibrosis: a
822 correlation with genotype? *Laryngoscope*, *124*(7), 1682-1686. doi:10.1002/lary.24575
- 823 Besser, J., Festen, J. M., Goverts, S. T., Kramer, S. E., & Pichora-Fuller, M. K. (2015). Speech-
824 in-speech listening on the LiSN-S test by older adults with good audiograms depends on
825 cognition and hearing acuity at high frequencies. *Ear Hear*, *36*(1), 24-41.
826 doi:10.1097/aud.0000000000000096
- 827 Best, V., Carlile, S., Jin, C., & van Schaik, A. (2005). The role of high frequencies in speech
828 localization. *J Acoust Soc Am*, *118*(1), 353-363. doi:10.1121/1.1926107
- 829 Borg, E., & Engström, B. (1982). Acoustic reflex after experimental lesions to inner and outer hair
830 cells. *Hear Res*, *6*(1), 25-34. doi:10.1016/0378-5955(82)90005-3
- 831 Brungart, D. S., & Simpson, B. D. (2009). Effects of bandwidth on auditory localization with a
832 noise masker. *J Acoust Soc Am*, *126*(6), 3199-3208. doi:10.1121/1.3243309
- 833 Cameron, S., & Dillon, H. (2007). Development of the Listening in Spatialized Noise-Sentences
834 Test (LISN-S). *Ear Hear*, *28*(2), 196-211. doi:10.1097/AUD.0b013e318031267f
- 835 Cepero, R., Smith, R. J., Catlin, F. I., Bressler, K. L., Furuta, G. T., & Shandera, K. C. (1987).
836 Cystic fibrosis--an otolaryngologic perspective. *Otolaryngol Head Neck Surg*, *97*(4), 356-
837 360. doi:10.1177/019459988709700403

- 838 Cheng, A. G., Johnston, P. R., Luz, J., Uluer, A., Fligor, B., Licameli, G. R., . . . Jones, D. T.
839 (2009). Sensorineural hearing loss in patients with cystic fibrosis. *Otolaryngol Head Neck*
840 *Surg*, 141(1), 86-90. doi:10.1016/j.otohns.2009.03.020
- 841 Cipolli, M., Canciani, M., Cavazzani, M., Uras, P., Zampieri, P., & Mastella, G. (1993). Ear
842 disease is not a common complication in cystic fibrosis. *Eur J Pediatr*, 152(3), 265-266.
843 doi:10.1007/bf01956160
- 844 Conway, S. P., Miller, M. G., Ramsden, C., & Littlewood, J. M. (1985). Intensive treatment of
845 pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin,
846 and netilmicin and ticarcillin. *Acta Paediatr Scand*, 74(1), 107-113. doi:10.1111/j.1651-
847 2227.1985.tb10929.x
- 848 Cystic Fibrosis Foundation. (2017). *Patient Registry Annual Data Report*. Retrieved from
849 Bethesda, Maryland:
- 850 Dell, B. (2018). CF Treatments Made Me Deaf, but Sound Is More Beautiful Than Ever Before.
851 *Cystic Fibrosis News Today*. Retrieved from
852 <https://cysticfibrosisnewstoday.com/2018/10/02/cystic-fibrosis-hearing-loss-deaf-sound/>
853 website:
- 854 Etymōtic Research. (2005). Bamford-Kowal-Bench Speech-in-Noise Test (Version 1.03) [Audio
855 CD]. Elk Grove Village, IL.
- 856 Fausti, S. A., Frey, R. H., Henry, J. A., Olson, D. J., & Schaffer, H. I. (1993). High-frequency
857 testing techniques and instrumentation for early detection of ototoxicity. *J Rehabil Res*
858 *Dev*, 30(3), 333-341.
- 859 Fausti, S. A., Helt, W. J., Phillips, D. S., Gordon, J. S., Bratt, G. W., Sugiura, K. M., & Noffsinger,
860 D. (2003). Early detection of ototoxicity using 1/6th-octave steps. *J Am Acad Audiol*, 14(8),
861 444-450.
- 862 Fausti, S. A., Henry, J. A., Helt, W. J., Phillips, D. S., Frey, R. H., Noffsinger, D., . . . Fowler, C.
863 G. (1999). An individualized, sensitive frequency range for early detection of ototoxicity.
864 *Ear Hear*, 20(6), 497-505. doi:10.1097/00003446-199912000-00005
- 865 Fausti, S. A., Henry, J. A., Schaffer, H. I., Olson, D. J., Frey, R. H., & McDonald, W. J. (1992).
866 High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity.
867 *J Infect Dis*, 165(6), 1026-1032. doi:10.1093/infdis/165.6.1026
- 868 Fausti, S. A., Larson, V. D., Noffsinger, D., Wilson, R. H., Phillips, D. S., & Fowler, C. G. (1994).
869 High-frequency audiometric monitoring strategies for early detection of ototoxicity. *Ear*
870 *Hear*, 15(3), 232-239. doi:10.1097/00003446-199406000-00004
- 871 Fausti, S. A., Rappaport, B. Z., Schechter, M. A., Frey, R. H., Ward, T. T., & Brummett, R. E.
872 (1984). Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation:
873 selected case studies. *Am J Otolaryngol*, 5(3), 177-182. doi:10.1016/s0196-
874 0709(84)80009-5
- 875 Filippone, E. J., Kraft, W. K., & Farber, J. L. (2017). The Nephrotoxicity of Vancomycin. *Clin*
876 *Pharmacol Ther*, 102(3), 459-469. doi:10.1002/cpt.726
- 877 Forcucci, R. A., & Stark, E. W. (1972). Hearing Loss, Speech-Language, and Cystic Fibrosis.
878 *Archives of Otolaryngology-Head & Neck Surgery*, 96(4), 361.
- 879 Forman-Franco, B., Abramson, A. L., Gorvoy, J. D., & Stein, T. (1979). Cystic fibrosis and hearing
880 loss. *Arch Otolaryngol*, 105(6), 338-342.
- 881 Garinis, A. C., Cornell, A., Allada, G., Fennelly, K. P., Maggiore, R. J., & Konrad-Martin, D.
882 (2018). Ototoxicity monitoring through the eyes of the treating physician: Perspectives

- 883 from pulmonology and medical oncology. *Int J Audiol*, 57(sup4), S19-s24.
884 doi:10.1080/14992027.2017.1381769
- 885 Garinis, A. C., Cross, C. P., Srikanth, P., Carroll, K., Feeney, M. P., Keefe, D. H., . . . Steyger, P.
886 S. (2017). The cumulative effects of intravenous antibiotic treatments on hearing in patients
887 with cystic fibrosis. *J Cyst Fibros*, 16(3), 401-409. doi:10.1016/j.jcf.2017.01.006
- 888 Gatehouse, S., & Noble, W. (2004). The Speech, Spatial and Qualities of Hearing Scale (SSQ). *Int*
889 *J Audiol*, 43(2), 85-99. doi:10.1080/14992020400050014
- 890 Geyer, L. B., Menna Barreto, S. S., Weigert, L. L., & Teixeira, A. R. (2015). High frequency
891 hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients.
892 *Braz J Otorhinolaryngol*, 81(6), 589-597. doi:10.1016/j.bjorl.2015.08.011
- 893 Goodman, A. (1965). Reference zero levels for pure-tone audiometer. *Asha*, 7(262), 1.
- 894 Guthrie, O. W. (2008). Aminoglycoside induced ototoxicity. *Toxicology*, 249(2-3), 91-96.
895 doi:10.1016/j.tox.2008.04.015
- 896 Handelsman, J. A., Nasr, S. Z., Pitts, C., & King, W. M. (2017). Prevalence of hearing and
897 vestibular loss in cystic fibrosis patients exposed to aminoglycosides. *Pediatr Pulmonol*,
898 52(9), 1157-1162. doi:10.1002/ppul.23763
- 899 Harris, P. A., Taylor, R., Minor, B. L., Elliott, V., Fernandez, M., O'Neal, L., . . . Duda, S. N.
900 (2019). The REDCap consortium: Building an international community of software
901 platform partners. *J Biomed Inform*, 95, 103208. doi:10.1016/j.jbi.2019.103208
- 902 Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research
903 electronic data capture (REDCap)--a metadata-driven methodology and workflow process
904 for providing translational research informatics support. *J Biomed Inform*, 42(2), 377-381.
905 doi:10.1016/j.jbi.2008.08.010
- 906 Heffner, H. E., & Heffner, R. S. (2008). High-frequency hearing. In P. Dallos, D. Oertel, & R.
907 Hoy (Eds.), *Handbook of the Senses: Audition* (pp. 55-60). New York: Elsevier.
- 908 Hirsch, I., Davis, H., Silverman, S., Reynolds, E., Eldert, E., ., & Benson, R. (1952). Development
909 of materials for speech audiometry. *J Speech Hear Disord*, 14, 321-337.
- 910 Huizing, E. H., & de Groot, J. C. (1987). Human cochlear pathology in aminoglycoside
911 ototoxicity--a review. *Acta Otolaryngol Suppl*, 436, 117-125.
912 doi:10.3109/00016488709124984
- 913 Hunter, L., & Blankenship, C. (2017). Middle Ear Measurement. In A. M. Tharpe & R. Seewald
914 (Eds.), *Comprehensive Handbook of Pediatric Audiology* (2nd ed.). Sand Diego, CA:
915 Plural Publishing.
- 916 Hunter, L., Blankenship, C., Sloat, N., Perdew, A., Stewart, H., & Moore, D. R. (2020a). Peripheral
917 Auditory Involvement in Childhood Listening Difficulty. *Ear Hear*.
- 918 Hunter, L. L., Monson, B. B., Moore, D. R., Sumitrajit, D., Wright, B. A., Monro, K. J., . . . Siegel,
919 J. H. (2020b). Extended high frequency hearing and speech perception implications in
920 adults and children. *Hear Res*.
- 921 International Organization for Standardization. (2004). ISO 389-8: Acoustics—Reference zero for
922 the calibration of audiometric equipment—Part 8: Reference equivalent threshold sound
923 pressure levels for pure tones and circumaural earphones.
- 924 International Organization for Standardization. (2017). ISO 389-1:Acoustics — Reference zero
925 for the calibration of audiometric equipment — Part 1: Reference equivalent threshold
926 sound pressure levels for pure tones and supra-aural earphones.
- 927 Jiang, M., Karasawa, T., & Steyger, P. S. (2017). Aminoglycoside-Induced Cochleotoxicity: A
928 Review. *Front Cell Neurosci*, 11, 308. doi:10.3389/fncel.2017.00308

- 929 Jorissen, M., De Boeck, K., & Feenstra, L. (1998). Middle ear disease in cystic fibrosis. *Int J*
930 *Pediatr Otorhinolaryngol*, 43(2), 123-128. doi:10.1016/s0165-5876(97)00172-9
- 931 Keefe, D. H., Feeney, M. P., Hunter, L. L., & Fitzpatrick, D. F. (2017). Aural Acoustic Stapedius-
932 Muscle Reflex Threshold Procedures to Test Human Infants and Adults. *J Assoc Res*
933 *Otolaryngol*, 18(1), 65-88. doi:10.1007/s10162-016-0599-z
- 934 Knight, K. R., Kraemer, D. F., & Neuwelt, E. A. (2005). Ototoxicity in children receiving platinum
935 chemotherapy: underestimating a commonly occurring toxicity that may influence
936 academic and social development. *J Clin Oncol*, 23(34), 8588-8596.
937 doi:10.1200/jco.2004.00.5355
- 938 Kreicher, K. L., Bauschard, M. J., Clemmens, C. S., Riva, C. M., & Meyer, T. A. (2018).
939 Audiometric assessment of pediatric patients with cystic fibrosis. *J Cyst Fibros*, 17(3), 383-
940 390. doi:10.1016/j.jcf.2017.10.007
- 941 Kulczycki, L. L., Butler, J. S., McCord-Dickman, D., & Herer, G. R. (1970). The Hearing of
942 Patients With Cystic Fibrosis. *Archives of Otolaryngology-Head & Neck Surgery*, 92(1),
943 54.
- 944 Levy, S. C., Freed, D. J., Nilsson, M., Moore, B. C., & Puria, S. (2015). Extended High-Frequency
945 Bandwidth Improves Speech Reception in the Presence of Spatially Separated Masking
946 Speech. *Ear Hear*, 36(5), e214-224. doi:10.1097/aud.0000000000000161
- 947 Lippmann, R. P. (1996). Accurate consonant perception without mid-frequency speech energy.
948 *IEEE Transactions on Speech and Audio Processing*, 4(1), 66.
- 949 Liu, K., Jiang, X., Shi, C., Shi, L., Yang, B., Shi, L., . . . Yang, S. (2013). Cochlear inner hair cell
950 ribbon synapse is the primary target of ototoxic aminoglycoside stimuli. *Mol Neurobiol*,
951 48(3), 647-654. doi:10.1007/s12035-013-8454-2
- 952 Magimairaj, B. M., Nagaraj, N. K., & Benafield, N. J. (2018). Children's Speech Perception in
953 Noise: Evidence for Dissociation From Language and Working Memory. *J Speech Lang*
954 *Hear Res*, 61(5), 1294-1305. doi:10.1044/2018_jslhr-h-17-0312
- 955 Martins, L., Guimarães, R. E., Becker, H. M., Bedran, M. B., Medeiros, M., & Camargos, P.
956 (2011). Low prevalence of middle ear disease in cystic fibrosis patients. *J Pediatr (Rio J)*,
957 87(1), 80-83. doi:10.2223/jped.2061
- 958 Martins, L. M., Camargos, P. A., Becker, H. M., Becker, C. G., & Guimaraes, R. E. (2010).
959 Hearing loss in cystic fibrosis. *Int J Pediatr Otorhinolaryngol*, 74(5), 469-473.
960 doi:10.1016/j.ijporl.2010.01.021
- 961 McCreery, R. W., Spratford, M., Kirby, B., & Brennan, M. (2017). Individual differences in
962 language and working memory affect children's speech recognition in noise. *Int J Audiol*,
963 56(5), 306-315. doi:10.1080/14992027.2016.1266703
- 964 McRorie, T. I., Bosso, J., & Randolph, L. (1989). Aminoglycoside ototoxicity in cystic fibrosis.
965 Evaluation by high-frequency audiometry. *Am J Dis Child*, 143(11), 1328-1332.
- 966 Moeller, M. P., Tomblin, J. B., Yoshinaga-Itano, C., Connor, C. M., & Jerger, S. (2007). Current
967 state of knowledge: language and literacy of children with hearing impairment. *Ear Hear*,
968 28(6), 740-753. doi:10.1097/AUD.0b013e318157f07f
- 969 Monson, B. B., Rock, J., Schulz, A., Hoffman, E., & Buss, E. (2019). Ecological cocktail party
970 listening reveals the utility of extended high-frequency hearing. *Hear Res*, 381, 107773.
971 doi:10.1016/j.heares.2019.107773
- 972 Motlagh Zadeh, L., Silbert, N. H., Sternasty, K., Swanepoel, W., Hunter, L. L., & Moore, D. R.
973 (2019). Extended high-frequency hearing enhances speech perception in noise. *Proc Natl*
974 *Acad Sci U S A*. doi:10.1073/pnas.1903315116

- 975 Mulheran, M., Degg, C., Burr, S., Morgan, D. W., & Stableforth, D. E. (2001). Occurrence and
976 risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose
977 aminoglycoside therapy. *Antimicrob Agents Chemother*, *45*(9), 2502-2509.
- 978 Mulherin, D., Fahy, J., Grant, W., Keogan, M., Kavanagh, B., & FitzGerald, M. (1991).
979 Aminoglycoside induced ototoxicity in patients with cystic fibrosis. *Ir J Med Sci*, *160*(6),
980 173-175.
- 981 Nilsson, M., Soli, S. D., & Sullivan, J. A. (1994). Development of the Hearing in Noise Test for
982 the measurement of speech reception thresholds in quiet and in noise. *J Acoust Soc Am*,
983 *95*(2), 1085-1099. doi:10.1121/1.408469
- 984 Northern, J. L., & Downs, M. P. (1984). *Hearing in children* (3rd Edition ed.). Baltimore:
985 Lippincott Williams & Wilkins.
- 986 O'Donnell, E. P., Scarsi, K. K., Scheetz, M. H., Postelnick, M. J., Cullina, J., & Jain, M. (2010).
987 Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients. *International*
988 *Journal Of Antimicrobial Agents*, *36*(1), 94-95. doi:10.1016/j.ijantimicag.2010.02.018
- 989 O'Sullivan, M. E., Perez, A., Lin, R., Sajjadi, A., Ricci, A. J., & Cheng, A. G. (2017). Towards the
990 Prevention of Aminoglycoside-Related Hearing Loss. *Front Cell Neurosci*, *11*, 325.
991 doi:10.3389/fncel.2017.00325
- 992 Ozcelik, T., Ozgirgin, N., Ozcelik, U., Gocmen, A., Gurcan, B., & Kiper, N. (1996). Auditory
993 nerve-brainstem responses in cystic fibrosis patients (Vol. 35, pp. 165-169).
- 994 Pauna, H. F., Monsanto, R. C., Kurata, N., Paparella, M. M., & Cureoglu, S. (2017). Changes in
995 the inner ear structures in cystic fibrosis patients. *Int J Pediatr Otorhinolaryngol*, *92*, 108-
996 114. doi:10.1016/j.ijporl.2016.11.013
- 997 Pedersen, S. S., Jensen, T., Osterhammel, D., & Osterhammel, P. (1987). Cumulative and acute
998 toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. *Antimicrob Agents*
999 *Chemother*, *31*(4), 594-599.
- 1000 Prescott, W. A., Jr. (2011). National survey of extended-interval aminoglycoside dosing in
1001 pediatric cystic fibrosis pulmonary exacerbations. *J Pediatr Pharmacol Ther*, *16*(4), 262-
1002 269. doi:10.5863/1551-6776-16.4.262
- 1003 Roup, C. M., Wiley, T. L., Safady, S. H., & Stoppenbach, D. T. (1998). Tympanometric Screening
1004 Norms for Adults. *Am J Audiol*, *7*(2), 55-60. doi:10.1044/1059-0889(1998/014)
- 1005 Scheenstra, R. J., Heijerman, H. G., Zuur, C. L., Touw, D. J., & Rijntjes, E. (2010). No hearing
1006 loss after repeated courses of tobramycin in cystic fibrosis patients. *Acta Otolaryngol*,
1007 *130*(2), 253-258. doi:10.3109/00016480903015150
- 1008 Scheenstra, R. J., Rijntjes, E., Tavy, D. L. J., Kingma, H., & Heijerman, H. G. M. (2009).
1009 Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic
1010 fibrosis patients. *Acta Otolaryngol*, *129*(1), 4-7. doi:10.1080/00016480801968534
- 1011 Seeto, A., & Searchfield, G. D. (2018). Investigation of Extended Bandwidth Hearing Aid
1012 Amplification on Speech Intelligibility and Sound Quality in Adults with Mild-to-
1013 Moderate Hearing Loss. *J Am Acad Audiol*, *29*(3), 243-254. doi:10.3766/jaaa.16180
- 1014 Seifert, C. M., Harvey, R. J., Mathews, J. W., Meyer, T. A., Ahn, C., Woodworth, B. A., &
1015 Schlosser, R. J. (2010). Temporal bone pneumatization and its relationship to paranasal
1016 sinus development in cystic fibrosis. *Rhinology*, *48*(2), 233-238. doi:10.4193/Rhin09.145
- 1017 Selimoglu, E. (2007). Aminoglycoside-induced ototoxicity. *Curr Pharm Des*, *13*(1), 119-126.
1018 doi:10.2174/138161207779313731
- 1019 Smyth, A. R. (2010). Minimizing the toxicity of aminoglycosides in cystic fibrosis. *J R Soc Med*,
1020 *103 Suppl 1*, S3-5. doi:10.1258/jrsm.2010.s11002

- 1021 Solmaz, F., Gundogdu, E., Akduman, D., Haksever, M., Dikici, O., & Unal, F. (2016). Does
1022 amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis? *Toxicol*
1023 *Rep*, 3, 401-404. doi:10.1016/j.toxrep.2016.03.010
- 1024 Sone, M., Schachern, P. A., & Paparella, M. M. (1998). Loss of spiral ganglion cells as primary
1025 manifestation of aminoglycoside ototoxicity. *Hear Res*, 115(1-2), 217-223.
- 1026 Stavroulaki, P., Vossinakis, I. C., Dinopoulou, D., Doudounakis, S., Adamopoulos, G., &
1027 Apostolopoulos, N. (2002). Otoacoustic emissions for monitoring aminoglycoside-induced
1028 ototoxicity in children with cystic fibrosis. *Arch Otolaryngol Head Neck Surg*, 128(2), 150-
1029 155. doi:10.1001/archotol.128.2.150
- 1030 Szaff, M., Hoiby, N., & Flensburg, E. W. (1983). Frequent antibiotic therapy improves survival of
1031 cystic fibrosis patients with chronic *Pseudomonas aeruginosa* infection. *Acta Paediatr*
1032 *Scand*, 72(5), 651-657. doi:10.1111/j.1651-2227.1983.tb09789.x
- 1033 Tan, K. H., Mulheran, M., Knox, A. J., & Smyth, A. R. (2003). Aminoglycoside prescribing and
1034 surveillance in cystic fibrosis. *Am J Respir Crit Care Med*, 167(6), 819-823.
1035 doi:10.1164/rccm.200109-012CC
- 1036 Tarshish, Y., Huang, L., Jackson, F. I., Edwards, J., Fligor, B., Wilkins, A., . . . Kenna, M. (2016).
1037 Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. *J Am Acad Audiol*, 27(1),
1038 6-12. doi:10.3766/jaaa.14104
- 1039 Thomsen, J., Friis, B., Jensen, K., Bak-Pedersen, K., & Larsen, P. K. (1979). Tobramycin
1040 ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis. *J*
1041 *Antimicrob Chemother*, 5(3), 257-260. doi:10.1093/jac/5.3.257
- 1042 Todd, N. W., & Martin, W. S. (1988). Temporal bone pneumatization in cystic fibrosis patients.
1043 *Laryngoscope*, 98(10), 1046-1049. doi:10.1288/00005537-198810000-00004
- 1044 Van Meter, D. J., Corriveau, M., Ahern, J. W., & Lahiri, T. (2009). A survey of once-daily dosage
1045 tobramycin therapy in patients with cystic fibrosis. *Pediatr Pulmonol*, 44(4), 325-329.
1046 doi:10.1002/ppul.20985
- 1047 Vitela, A. D., Monson, B. B., & Lotto, A. J. (2015). Phoneme categorization relying solely on
1048 high-frequency energy. *J Acoust Soc Am*, 137(1), E165-70. doi:10.1121/1.4903917
- 1049 Yeend, I., Beach, E. F., & Sharma, M. (2019). Working Memory and Extended High-Frequency
1050 Hearing in Adults: Diagnostic Predictors of Speech-in-Noise Perception. *Ear Hear*, 40(3),
1051 458-467. doi:10.1097/aud.0000000000000640
- 1052 Yildirim, N., Sone, M., Mutlu, C., Schachern, P. A., Paparella, M. M., & Le, C. T. (2000).
1053 Histopathologic features of the temporal bone in patients with cystic fibrosis. *Arch*
1054 *Otolaryngol Head Neck Surg*, 126(1), 75-78. doi:10.1001/archotol.126.1.75
- 1055 Yoshinaga-Itano, C. (1999). Benefits of early intervention for children with hearing loss.
1056 *Otolaryngol Clin North Am*, 32(6), 1089-1102. doi:10.1016/s0030-6665(05)70196-1
- 1057 Yoshinaga-Itano, C. (2003). From Screening to Early Identification and Intervention: Discovering
1058 Predictors to Successful Outcomes for Children With Significant Hearing Loss. *J Deaf*
1059 *Stud Deaf Educ*, 8(1), 11-30. doi:10.1093/deafed/8.1.11
- 1060 Zettner, E. M., & Folsom, R. C. (2003). Transient emission suppression tuning curve attributes in
1061 relation to psychoacoustic threshold. *J Acoust Soc Am*, 113(4 Pt 1), 2031-2041.
1062 doi:10.1121/1.1560191
- 1063 Zettner, E. M., & Gleser, M. A. (2018). Progressive Hearing Loss among Patients with Cystic
1064 Fibrosis and Parenteral Aminoglycoside Treatment. *Otolaryngol Head Neck Surg*, 159(5),
1065 887-894. doi:10.1177/0194599818782444
- 1066

Figure 1.




Figure 2.




Figure 3.




Figure 4.




Table 1. Study sample demographics, questionnaire, and hearing loss characteristics for all participants combined, as well as the CF and control groups.

	All	CF	Control	<i>p</i> -value
Number of Participants	118	57	61	
Age at Test				0.534‡
Mean (SD)	14.77 (3.28)	14.96 (3.63)	14.59 (2.94)	
Range	6.0-21.1	6.0-21.0	7.5-21.1	
Sex*				0.678#
Male	52 (44.07)	24 (42.11)	28 (45.90)	
Female	66 (55.93)	33 (57.89)	33 (54.10)	
Race*				0.017^
Caucasian	108 (91.53)	56 (98.25)	52 (85.25)	
Non-Caucasian	10 (8.47)	1 (1.75)	9 (14.75)	
Hearing and Balance Questionnaire*				
Hearing Problem	23 (19.49)	18 (31.57)	5 (8.19)	0.001#
Tinnitus	39 (33.05)	30 (52.63)	9 (16.07)	<0.001#
Balance Issues	23 (19.49)	18 (31.57)	5 (8.92)	0.003#
History of Otitis Media	40 (33.89)	24 (42.10)	16 (26.22)	0.049#
PE Tubes	16 (13.55)	9 (15.78)	7 (11.47)	0.412#
Previous Hearing Test	97 (82.20)	47 (82.45)	50 (89.28)	0.919#
Hearing Status†				
Normal	126 (53.39)	49 (42.98)	77 (63.11)	–
Hearing Loss	110 (46.61)	65 (57.02)	41 (36.89)	–
Hearing Loss Frequency Range†				
Standard Frequency	64 (27.59)	43 (37.72)	21 (17.21)	–
Extended High Frequency	91 (39.22)	54 (47.37)	37 (30.33)	–
Degree of Hearing Loss†				
Slight	53 (22.46)	24 (21.05)	29 (23.77)	–
Mild	27 (11.44)	15 (13.16)	12 (9.84)	–
Moderate	21 (8.09)	18 (15.79)	3 (2.46)	–
Moderate-Severe	6 (2.54)	5 (4.39)	1 (0.82)	–
Severe	3 (1.27)	3 (2.63)	0 (0.00)	–
Type of Hearing Loss†				
Conductive	8 (3.39)	6 (5.26)	2 (1.64)	–
Sensorineural	82 (34.75)	47 (41.23)	35 (28.69)	–
Mixed	18 (7.63)	12 (10.53)	6 (4.92)	–
Undetermined	2 (0.85)	0 (0.00)	2 (1.64)	–

Note: PE = Pressure Equalizer Tube, * = number (%) of participants, † = number (%) of ears, ‡ = Two-Sample t-test, # = Chi-Square test, ^ Fisher's Exact Test

Table 2. Mixed model repeated measures analysis, with *p*-values and F-test (Degrees of Freedom) displayed for factors included in the final model.

	Group	Test Frequency	Group* Frequency	Hearing Status	Group* Hearing Status	Ear	Age	Sex	Race
Audiometric Threshold	<0.001	<0.001	0.002	–	–	0.541	0.094	0.349	0.004
F (DF = 262 to 1524)	162.18	37.12	2.94	–	–	0.37	2.81	0.88	8.50
Tympanometry									
Peak Pressure	0.537	–	–	0.001 [^]	–	0.593	0.291	0.002	0.351
F (DF = 217)	0.38	–	–	14.67	–	0.29	1.12	10.00	0.87
Tympanometric Width	0.156	–	–	0.614 [^]	–	0.565	0.175	0.144	0.088
F (DF = 209 to 212)	2.03	–	–	0.49	–	0.33	1.85	2.15	2.94
Admittance	0.002	–	–	0.127 [^]	0.041 [^]	0.612	0.096	0.733	0.299
F (DF = 211 to 215)	10.35	–	–	2.09	3.23	0.26	2.80	0.12	1.09
MEMR BBN									
Ipsilateral	0.042	–	–	<0.001*	–	0.352	0.051	0.972	0.392
F (DF = 191)	4.20	–	–	14.19	–	0.87	3.86	<0.00	0.74
Contralateral	0.004	–	–	0.001*	–	0.800	0.224	0.583	0.462
F (DF = 183 to 185)	8.30	–	–	12.42	–	0.06	1.49	0.30	0.54
Speech Perception									
SNR-Loss	<0.001	–	–	0.045*	–	0.328	0.899	0.017	0.302
F (DF = 181 to 182)	23.95	–	–	4.07	–	0.96	0.02	5.83	1.07
SRT	<0.001	–	–	–	–	0.404	0.796	0.469	0.894
F (DF = 190-191)	30.77	–	–	–	–	0.70	0.07	0.53	0.02

* Hearing status was defined as the presence of hearing loss (> 15 dB HL) at any test frequency (0.25 to 16 kHz)

[^] Hearing status was categorized into three groups including normal hearing, conductive or mixed hearing loss, and sensorineural hearing loss

